CPHI [CHINA PHARMA] 10-K: o x x o Large accelerated filer o

[o x x o Large accelerated filer o Accelerated filer o Non-accelerated filer Do not check if a smaller reporting company x Smaller reporting company ¨ x Documents Incorporated by Reference: None. 2 FORM 10-K ANNUAL REPORT FISCAL YEAR ENDED DECEMBER 31, 2014 TABLE OF CONTENTS PAGE PART I] [Re: Service about being [Job Position] of China Pharma Holdings, Inc. [Date/Month/Year] Dear [ ], On behalf of the Board of Directors (the “Board”) of China Pharma Holdings, Inc. (the “Company”), I am pleased to welcome you to join the Board as [Job Position]. I look forward to working with you. Your starting date will be the date on which] [Loans Extension Confirmation Letter Reference is made to the loans from Ms. Heung Mei Tsui to China Pharma Holdings, Inc. (the “Company”), the principal and accumulated interest totaled USD1,354,567 and USD44,213 respectively as of December 31, 2014. Due to the fact the Company temporarily did not have enough balance in its oversea account to repay the loans, both Ms. Tsui] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement No. 333-141734 Post-Effective Amendment No. 1 to Form SB-2 on Form S-3 of our report dated March 30, 2015 relating to the consolidated financial statements of China Pharma Holdings, Inc. and subsidiaries as of and for the year ended December 31, 2014 appearing] [CERTIFICATION OF OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-K of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-K of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: March 30, 2015 President and Chief Executive Officer (principal financial officer and principal accounting officer) EX-32.1 7 cphi10kex321123114.htm]

By | 2016-03-28T19:22:42+00:00 March 30th, 2015|Categories: Chinese Stocks, CPHI, Webplus ver|Tags: , , , , , |0 Comments

TPI [TIANYIN PHARMACEUTICAL] 10-Q: (Original Filing)

[] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER I, Guoqing Jiang, certify that: 1. I have reviewed this quarterly report on Form 10-Q for the period ended December 31, 2014 of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make] [CERTIFICATION OF CHIEF FINANCIAL OFFICER I, Guoqing Jiang, certify that: 1. I have reviewed this quarterly report on Form 10-Q for the period ended December 31, 2014 of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Guoqing Jiang Chief Executive Officer, Chief Accounting Officer, Chairman EX-32.1 4 f10q1214ex32i_tianyinpharma.htm CERTIFICATION] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Guoqing Jiang Acting Chief Financial Officer EX-32.2 5 f10q1214ex32ii_tianyinpharma.htm CERTIFICATION]

By | 2016-03-19T14:42:49+00:00 March 13th, 2015|Categories: Chinese Stocks, SEC Original, TPI|Tags: , , , , , |0 Comments

TPI [TIANYIN PHARMACEUTICAL] 8-K: (Original Filing)

[CHENGDU, China, Feb. 26, 2015 /PRNewswire/ - Tianyin Pharmaceutical Inc. (NYSE MKT: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API), received notice on February 24, 2015 from the NYSE MKT LLC (the "Exchange") indicating that the Company is below certain of the Exchange's continued listing standards,] []

By | 2016-03-19T14:45:10+00:00 February 26th, 2015|Categories: Chinese Stocks, SEC Original, TPI|Tags: , , , , , |0 Comments

TPI [TIANYIN PHARMACEUTICAL] 8-K: CHENGDU, China, Feb. 26, 2015 /PRNewswire/ – Tianyin

[CHENGDU, China, Feb. 26, 2015 /PRNewswire/ - Tianyin Pharmaceutical Inc. (NYSE MKT: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API), received notice on February 24, 2015 from the NYSE MKT LLC (the "Exchange") indicating that the Company is below certain of the Exchange's continued listing standards,] []

By | 2016-03-19T14:46:48+00:00 February 26th, 2015|Categories: Chinese Stocks, TPI, Webplus ver|Tags: , , , , , |0 Comments

SVA [SINOVAC BIOTECH] SC 13G: (Original Filing)

[SCHEDULE 13G (Amendment No. )* Sinovac Biotech Ltd. (Name of Issuer) Common Stock (Title of Class of Securities) P8696W104 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) x Rule 13d-1(b) o Rule 13d-1(c) o Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this]

By | 2016-03-16T06:50:30+00:00 February 17th, 2015|Categories: Chinese Stocks, SEC Original, SVA|Tags: , , , , , |0 Comments

SVA [SINOVAC BIOTECH] SC 13G: SCHEDULE 13G (Amendment No. )* Sinovac Biotech Ltd.

[SCHEDULE 13G (Amendment No. )* Sinovac Biotech Ltd. (Name of Issuer) Common Stock (Title of Class of Securities) P8696W104 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) x Rule 13d-1(b) o Rule 13d-1(c) o Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this]

By | 2016-03-16T06:52:29+00:00 February 17th, 2015|Categories: Chinese Stocks, SVA, Webplus ver|Tags: , , , , , |0 Comments
Skip to toolbar